7Baggers

We provide you with 20 years of free, institutional-grade data for RAPT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RAPT. Explore the full financial landscape of RAPT stock.

Reported DateCIKTickerType
2023-11-131673772RAPT10-QUrl
2023-08-111673772RAPT10-QUrl
2023-05-111673772RAPT10-QUrl
2023-03-141673772RAPT10-KUrl
2022-11-101673772RAPT10-QUrl
2022-08-111673772RAPT10-QUrl
2022-05-111673772RAPT10-QUrl
2022-03-101673772RAPT10-KUrl
2021-11-101673772RAPT10-QUrl
2021-08-111673772RAPT10-QUrl
2021-05-111673772RAPT10-QUrl
2021-03-111673772RAPT10-KUrl
2020-11-161673772RAPT10-QUrl
2020-08-131673772RAPT10-QUrl
2020-05-141673772RAPT10-QUrl
2020-03-301673772RAPT10-KUrl
2020-02-041673772RAPTS-1Url
2019-12-111673772RAPT10-QUrl
2019-07-051673772RAPTS-1Url

RAPT Therapeutics, Inc
(NASDAQ:RAPT) 

RAPT stock logo

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small m...

Founded: 2015
Full Time Employees: 71
CEO: Brian Russell Wong  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about RAPT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.